U.S. Energy Services Stock News

NasdaqGS:SVRA
NasdaqGS:SVRABiotechs

Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and granted the therapy Priority Review, with a PDUFA action date set for August 22, 2026. The drug’s combination of Priority Review, Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations highlights both its potential clinical importance and the high...
NYSE:TFC
NYSE:TFCBanks

Is Truist Financial (TFC) Pricing Reflect Its Recent Returns And Valuation Metrics

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...
NYSE:XPEV
NYSE:XPEVAuto

Is XPeng (XPEV) Pricing In Too Much Hope After Prolonged Share Price Weakness

If you are wondering whether XPeng shares are pricing in too much hope or not enough, this article walks through what the current valuation really implies for investors. The stock recently closed at US$16.99, with returns of a 3.2% decline over 7 days, a 5.5% decline over 30 days, a 16.8% decline year to date, a 16.1% decline over 1 year and an 81.3% decline over 3 years, which gives a mixed picture of sentiment and risk. Recent headlines around XPeng have focused on broad themes such as...
NasdaqGS:VISN
NasdaqGS:VISNCommunications

Assessing Vistance Networks (VISN) Valuation After 2025 Results And Connectivity And Cable Solutions Sale

Vistance Networks (VISN) drew fresh attention after reporting 2025 results that included very large net income and a move from loss to profit, supported by the sale of its Connectivity and Cable Solutions segment. See our latest analysis for Vistance Networks. The share price reaction has been mixed, with a 1 day share price return of 1.59% after the results, a 90 day share price return showing an 8.51% decline, and a 1 year total shareholder return of very large magnitude that reflects how...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

A Look At Booking Holdings (BKNG) Valuation After Mixed Short And Long Term Share Performance

Recent share performance and business snapshot Booking Holdings (BKNG) has drawn investor attention after a period of mixed share performance, with gains over the past week contrasting with weaker returns over the past month and over the past 3 months. The company, headquartered in Norwalk, Connecticut, runs platforms such as Booking.com, Priceline, Agoda, KAYAK and OpenTable, generating revenue of US$26.9b and net income of US$5.4b from global travel and restaurant reservation services. See...
NasdaqGS:PENN
NasdaqGS:PENNHospitality

Is PENN Entertainment (PENN) Now Attractively Priced After Recent Share Price Rebound?

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...
NasdaqCM:CMPX
NasdaqCM:CMPXBiotechs

How Palo Alto’s New Stake and Rising Institutional Ownership At Compass Therapeutics (CMPX) Has Changed Its Investment Story

Palo Alto Investors LP opened a new position in Compass Therapeutics in the fourth quarter of 2025, acquiring 2,532,419 shares valued at about US$13.6 million, or roughly 1.89% of its assets under management. This move, alongside expectations for Compass’s bispecific antibody Tovecimig (CTX-009) in biliary tract cancer, highlights growing institutional interest in its oncology pipeline. Next, we will examine how rising institutional ownership, anchored by Palo Alto Investors’ new stake,...
NYSE:GVA
NYSE:GVAConstruction

Is It Too Late To Consider Granite Construction (GVA) After A 65% One Year Surge?

If you are wondering whether Granite Construction's share price still offers value after a strong run, or if most of the upside is already reflected, this article breaks down what the current market price might be implying. The stock most recently closed at US$133.84, with a 7 day return of a 0.7% decline, a 30 day return of 10.8%, a year to date return of 12.8%, a 1 year return of 65.3%, a 3 year return that is very large, and a 5 year return that is very large. Recent price moves sit...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

Is SPS Commerce (SPSC) Now Attractive After A 55% One Year Share Price Slump

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...
NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Veracyte (VCYT) Valuation Check After Mixed Short And Long Term Share Price Performance

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...
NYSE:VIRT
NYSE:VIRTCapital Markets

Why Virtu Financial (VIRT) Is Up 6.9% After Blockbuster Q4 and New Crypto Ambitions

In late February 2026, Virtu Financial reported Q4 2025 results showing its highest quarterly adjusted net income since early 2021, supported by elevated market volatility and strong trading volumes across both Market Making and Execution Services. An interesting angle for investors is Virtu’s plan to channel this momentum into higher trading capital, upgraded infrastructure, and moves into emerging areas such as prediction markets and crypto. We’ll now explore how this stronger quarter,...
NasdaqGS:ZBIO
NasdaqGS:ZBIOBiotechs

The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Obexelimab’s Commercial Pivot And Cash War Chest

Zenas BioPharma has recently been highlighted for moving from a pre-revenue stage toward commercialization of its lead antibody therapy obexelimab, targeting IgG4-Related Disease, an area with no approved treatments. An interesting aspect of this story is Zenas’ reported cash position of about US$270,000,000 entering 2026, which supports its plans to expand a pipeline focused on B‑cell‑mediated autoimmune diseases while advancing obexelimab toward market. Against this backdrop, we’ll examine...
NYSE:FLR
NYSE:FLRConstruction

Is Fluor (FLR) Pricing Reflect Recent 38% Rally And Mixed Valuation Signals

If you are looking at Fluor and wondering whether the current share price gives you good value, you are not alone. This article focuses squarely on what you might be paying for compared to what you are getting. After closing at US$50.91, the stock has seen a 1.4% decline over the last 7 days, a 10.2% gain over 30 days, a 22.1% return year to date, and a 37.9% return over the past year, which may change how investors think about both upside and risk. Recent attention on Fluor has been driven...
NYSE:AAP
NYSE:AAPSpecialty Retail

Assessing Advance Auto Parts (AAP) Valuation After Its Recent Share Price Rebound

Advance Auto Parts (AAP) is back on many investors’ screens after its share price returned 37% year to date, even though 3 year and 5 year total returns remain deeply negative. See our latest analysis for Advance Auto Parts. That 36.98% year to date share price return and 53.92% 1 year total shareholder return suggest improving sentiment around Advance Auto Parts, even though the 3 and 5 year total shareholder returns remain sharply negative. If this rebound has you thinking about what else...
NYSE:XZO
NYSE:XZOInsurance

Exzeo Group Flood Partnership Tests Valuation Concerns And Growth Hopes

Exzeo Group has entered into a new partnership with Tokio Marine Highland to distribute TMH2O residential flood insurance. The collaboration expands Exzeo’s property insurance offerings and supports its ambitions as a multi-line, technology driven platform. For investors tracking NYSE:XZO, this announcement comes as the stock trades at $16.1, with a 3.7% gain over the past week and a 20.8% decline over the past month. Year to date, shares show a 29.3% decline, so this move may stand out as...
NasdaqGS:FSLR
NasdaqGS:FSLRSemiconductor

Is First Solar (FSLR) Pricing Look Attractive After Recent Share Price Pullback

If you are wondering whether First Solar's current share price reflects its true worth, this article will walk through how that value stacks up against a range of valuation checks. The stock last closed at US$199.86, with a 17.5% decline over the past 7 days and an 11.4% decline over the past 30 days, although the 1 year return sits at 56.6% and the 5 year return at 179.7%. These moves come as First Solar continues to sit in the spotlight of the wider solar and semiconductor industry, with...
NasdaqCM:SBET
NasdaqCM:SBETHospitality

Sharplink (SBET) Valuation In Focus As Ethereum Rally Lifts Its Treasury-Linked Business Model

Ethereum rally puts Sharplink’s treasury model in focus Sharplink (SBET) is back on watch after Ethereum’s latest rally, with the company’s large ETH treasury and staking driven business model pulling the stock closely in line with crypto market moves. See our latest analysis for Sharplink. At a share price of US$7.39, Sharplink’s stock has recently swung higher with a 1-day share price return of 8.36% and a 7-day share price return of 13.87%. These short bursts follow a weaker patch marked...
NYSE:CRL
NYSE:CRLLife Sciences

Assessing Charles River Laboratories (CRL) Valuation After Recent Mixed Share Price Performance

Event overview and recent share performance Charles River Laboratories International (CRL) has drawn investor attention after recent share price moves, with the stock flat over the past day, up about 9% over the past week, but showing a 15% decline over the past month. Over the past 3 months, Charles River has posted a small positive total return, while year to date the stock is down about 12%. Over the past year, it has delivered roughly 9% total return, set against weaker 3 year and 5 year...
NYSE:VG
NYSE:VGOil and Gas

US Stock Market Today S&P 500 Futures Fall On Rising Yield And Inflation Worries

The Morning Bull - US Market Morning Update Tuesday, Mar, 3 2026 US stock futures are pointing lower this morning, with E mini S&P 500 contracts down about 1.5%, the Nasdaq 100 futures off nearly 2% and small cap Russell 2000 futures lower by about 2.6%. The pressure comes as the US 10 year Treasury yield holds near 4.04%, which keeps borrowing costs elevated for households and businesses, and as global government bond yields in the UK and Europe climb on renewed inflation worries tied to...
NYSE:HAE
NYSE:HAEMedical Equipment

Assessing Haemonetics (HAE) Valuation After FDA Clearance Of NexSys PCS Persona PLUS System

Haemonetics (HAE) is back in focus after receiving FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS, a next-generation platform designed to tailor plasma collection volumes to individual donors. See our latest analysis for Haemonetics. Despite the FDA clearance and recent conference appearance, Haemonetics’ share price, last closing at $63.88, shows mixed momentum. The stock has a 4.23% 7 day share price return, but a 20.13% decline year to date and a 20.93%...
NYSE:MTDR
NYSE:MTDROil and Gas

Is It Too Late To Consider Matador Resources (MTDR) After Its Recent Share Price Surge

If you are wondering whether Matador Resources at around US$54.12 is priced attractively or already baking in a lot of optimism, you are not alone. The stock has returned 5.8% over the last 7 days, 19.6% over the last 30 days, 24.8% year to date, 16.9% over 1 year, 0.7% over 3 years and 131.2% over 5 years, which naturally raises questions about what is already reflected in the price. Recent attention on Matador Resources has focused on its position in the US energy sector and how investors...
NYSE:GS
NYSE:GSCapital Markets

Lloyd Blankfein Flags Shadow Banking Risks For Goldman Sachs Investors

Former Goldman Sachs (NYSE:GS) CEO Lloyd Blankfein has warned of potential systemic risks tied to the rapid expansion of private credit and shadow banking. His comments focus on hidden leverage and illiquid assets that may sit outside traditional bank balance sheets. The warning comes as investors pay closer attention to how credit risk is distributed across banks, non bank lenders, and the broader financial system. Goldman Sachs is a global investment bank and financial services firm...
NYSE:PSTG
NYSE:PSTGTech

Assessing Everpure (PSTG) Valuation After Strong Results Guidance And Share Buybacks

Why Everpure’s latest earnings matter for shareholders Everpure (PSTG) has drawn fresh attention after reporting fourth quarter and full year results alongside new revenue guidance and an update on its share repurchase activity, giving investors several moving pieces to assess. For the fourth quarter ended February 1, 2026, the company reported revenue of US$1,058.9 million, compared with US$879.84 million a year earlier. Net income for the period was US$100.25 million versus US$42.44 million...
NYSE:ALK
NYSE:ALKAirlines

Is Alaska Air Group (ALK) Pricing Reflect Recent Airline Sector Risks Accurately

If you are wondering whether Alaska Air Group is attractively priced at its current level, looking closely at how its valuation stacks up against its fundamentals can help frame that decision. The stock last closed at US$50.77, with returns of 0.3% over the past 7 days, a 0.1% decline over 30 days, a 1.5% decline year to date, a 27.4% decline over 1 year, a 6.0% gain over 3 years and a 25.3% decline over 5 years, which gives you a mixed picture of recent and longer term performance. Recent...